Cullinan Therapeutics closed at $12.49 on Nov 4, down 20.70%, 45.6% below its 52-week closing high. Volume of 2.2M shares was 3.27× its 20-day average (well above normal).
Split-adjusted performance: -23.1% over one month, -16.7% over six months, +59.9% over one year.
Short interest was 7.6M shares at the Oct 15 settlement (14.3% of float, 8.2 days to cover).
No reported quarters with price history yet.
Percentile among 139 companies (100 = best)
Industry medians: 6-month return −19.2%, revenue growth +8.8%, net margin −312.9%, P/E 22.0×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| CGEMCullinan Therapeutics | $12.49 | −20.70% | −16.7% | — | — | — | $803.8M | |
| DNAGinkgo Bioworks Holdings | $11.65 | +8.27% | +15.6% | −48.5% | −231.7% | — | $784.5M | Compare |
| SANASana Biotechnology | $2.56 | +4.92% | −29.7% | — | — | — | $766.4M | Compare |
| PRMEPrime Medicine | $4.97 | +9.23% | +45.7% | +3.5% | −3649.0% | — | $901.4M | Compare |
| MGTXMeiraGTx Holdings | $9.42 | −1.05% | −4.8% | +8608.6% | 50.0% | 11.5 | $904.7M | Compare |
| ATTOAttovia Therapeutics | $15.60 | +2.16% | — | — | — | — | $712.2M | Compare |
| GLUEMonte Rosa Therapeutics | $10.82 | +3.94% | −46.9% | −61.3% | −483.9% | — | $923.1M | Compare |
| SLDBSolid Biosciences | $6.52 | +3.82% | −9.4% | — | — | — | $699.1M | Compare |
| CADLCandel Therapeutics | $9.05 | +2.61% | +18.6% | — | — | — | $692.5M | Compare |
Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
